1254 related articles for article (PubMed ID: 22827246)
41. Vaccine-associated paralytic poliomyelitis and other diseases with acute flaccid paralysis syndrome in Belarus.
Samoilovich EO; Feldman EV; Yermalovich MA; Protas II; Titov LP
Cent Eur J Public Health; 2003 Dec; 11(4):213-8. PubMed ID: 14768785
[TBL] [Abstract][Full Text] [Related]
42. Three cases of paralytic poliomyelitis associated with type 3 vaccine poliovirus strains in Bulgaria.
Korsun N; Kojouharova M; Vladimirova N; Fiore L; Litvinenko I; Buttinelli G; Fiore S; Voynova-Georgieva V; Mladenova Z; Georgieva D
J Med Virol; 2009 Sep; 81(9):1661-7. PubMed ID: 19626606
[TBL] [Abstract][Full Text] [Related]
43. Strategic Response to an Outbreak of Circulating Vaccine-Derived Poliovirus Type 2 - Syria, 2017-2018.
Mbaeyi C; Wadood ZM; Moran T; ; Ather F; Stehling-Ariza T; Nikulin J; Al Safadi M; Iber J; Zomahoun L; Abourshaid N; Pang H; Collins N; Asghar H; Butt OUI; Burns CC; Ehrhardt D; Sharaf M
MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(24):690-694. PubMed ID: 29927908
[TBL] [Abstract][Full Text] [Related]
44. Imported vaccine-associated paralytic poliomyelitis--United States, 2005.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2006 Feb; 55(4):97-9. PubMed ID: 16456525
[TBL] [Abstract][Full Text] [Related]
45. Neurologic complications associated with oral poliovirus vaccine and genomic variability of the vaccine strains after multiplication in humans.
Friedrich F
Acta Virol; 1998 Jun; 42(3):187-94. PubMed ID: 9842449
[TBL] [Abstract][Full Text] [Related]
46. Oral poliovaccine: will it help eradicate polio or cause the next epidemic?
Shulman LM; Manor Y; Sofer D; Swartz T; Mendelson E
Isr Med Assoc J; 2006 May; 8(5):312-5. PubMed ID: 16805227
[TBL] [Abstract][Full Text] [Related]
47. A Cluster of Paralytic Poliomyelitis Cases Due to Transmission of Slightly Diverged Sabin 2 Vaccine Poliovirus.
Korotkova EA; Gmyl AP; Yakovenko ML; Ivanova OE; Eremeeva TP; Kozlovskaya LI; Shakaryan AK; Lipskaya GY; Parshina IL; Loginovskikh NV; Morozova NS; Agol VI
J Virol; 2016 Jul; 90(13):5978-88. PubMed ID: 27099315
[TBL] [Abstract][Full Text] [Related]
48. A case for developing antiviral drugs against polio.
Collett MS; Neyts J; Modlin JF
Antiviral Res; 2008 Sep; 79(3):179-87. PubMed ID: 18513807
[TBL] [Abstract][Full Text] [Related]
49. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
Duintjer Tebbens RJ; Thompson KM
J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871
[TBL] [Abstract][Full Text] [Related]
50. [Circulating vaccine-derived poliovirus type 2 outbreak in Democratic Republic of Congo 2011-2012].
Bazira L; Coulibaly T; Mayenga M; Ncharre C; Yogolelo R; Mbule A; Moudzeo H; Lwamba P; Mulumba AW; Cabore J
Bull Soc Pathol Exot; 2015 Oct; 108(4):235-41. PubMed ID: 26288132
[TBL] [Abstract][Full Text] [Related]
51. Successful control of poliomyelitis by a combined OPV/IPV polio vaccine program in the West Bank and Gaza, 1978-93.
Tulchinsky T; Abed Y; Handsher R; Toubassi N; Acker C; Melnick J
Isr J Med Sci; 1994; 30(5-6):489-94. PubMed ID: 8034509
[TBL] [Abstract][Full Text] [Related]
52. Use of mutational pattern in 5'-NCR and VP1 regions of polioviruses for molecular diagnosis.
Pliaka V; Dedepsidis E; Kyriakopoulou Z; Papadopoulou I; Levidiotou S; Markoulatos P
Mol Cell Probes; 2007 Aug; 21(4):267-75. PubMed ID: 17336496
[TBL] [Abstract][Full Text] [Related]
53. Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission.
Aylward RB; Cochi SL
Bull World Health Organ; 2004 Jan; 82(1):40-6. PubMed ID: 15106299
[TBL] [Abstract][Full Text] [Related]
54. [The perspective of global eradication of poliomyelitis].
Knolle H; Egli A; Candrian U
Gesundheitswesen; 2004 Jan; 66(1):1-6. PubMed ID: 14767784
[TBL] [Abstract][Full Text] [Related]
55. Possible global strategies for stopping polio vaccination and how they could be harmonized.
Cochi SL; Sutter RW; Aylward RB
Dev Biol (Basel); 2001; 105():153-8; discussion 159. PubMed ID: 11763323
[TBL] [Abstract][Full Text] [Related]
56. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP).
Prevots DR; Burr RK; Sutter RW; Murphy TV;
MMWR Recomm Rep; 2000 May; 49(RR-5):1-22; quiz CE1-7. PubMed ID: 15580728
[TBL] [Abstract][Full Text] [Related]
57. [Genetic evolution of poliovirus: success and difficulties in the eradication of paralytic poliomyelitis].
Blondel B; Autret A; Brisac C; Pelletier I; Martin-Latil S; Jegouic S; Bessaud M; Joffret ML; Balanant J; Colbère-Garapin F; Delpeyroux F
Med Trop (Mars); 2008 Apr; 68(2):189-202. PubMed ID: 18630055
[TBL] [Abstract][Full Text] [Related]
58. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus.
Kew O; Morris-Glasgow V; Landaverde M; Burns C; Shaw J; Garib Z; André J; Blackman E; Freeman CJ; Jorba J; Sutter R; Tambini G; Venczel L; Pedreira C; Laender F; Shimizu H; Yoneyama T; Miyamura T; van Der Avoort H; Oberste MS; Kilpatrick D; Cochi S; Pallansch M; de Quadros C
Science; 2002 Apr; 296(5566):356-9. PubMed ID: 11896235
[TBL] [Abstract][Full Text] [Related]
59. Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication.
Modlin JF; Bandyopadhyay AS; Sutter R
J Infect Dis; 2021 Sep; 224(12 Suppl 2):S398-S404. PubMed ID: 34590135
[TBL] [Abstract][Full Text] [Related]
60. Circulating vaccine derived polio viruses and their impact on global polio eradication.
Wagner BG; Earn DJ
Bull Math Biol; 2008 Jan; 70(1):253-80. PubMed ID: 17934778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
